• Home Study Details

  • Home / Learn / Home Study CE / Home Study Details


Movement Beyond Laxatives: Evolving Pharmacologic Options for IBS-C and CIC

Program Type

OnDemand

Credits

1 Contact Hour(s)

Release Date

Sunday, July 15, 2018

Offline Date:

Tuesday, January 15, 2019

ACPE Expiration Date

Monday, May 17, 2021

Target Audience

Nurse, Pharmacist, Pharmacy Technician

Cost

$0.00

  • Overview

    IBS-C and CIC are highly prevalent conditions that negatively impact Quality of Life and pose a significant economic burden on the healthcare system. Because so many patients self-treat the conditions, estimates of the number of Americans that suffer from IBS-C and CIC vary widely ranging from 2% to 27% of the population. Despite the $400 million dollars that are spent on laxatives each year, constipation still accounts for 2.5 million physician visits annually in the U.S. revealing a desperate need for improved patient counseling and knowledge of pharmacologic options beyond laxatives in pharmacies around the nation where millions of patients seek pharmacist recommendations. When traditional treatments, such as dietary manipulation and standard laxatives do not adequately treat or fail to treat IBS-C and CIC, pharmacists must be prepared to educate patients regarding the pharmacologic options available to relieve these frustrating and costly conditions.

    Rating


    Handouts

    Slide Document:   18066H01_4pp.pdf
    Slide Document:   18066H01_2pp.pdf

    Financial Support By

    Synergy Pharmaceuticals
  • Nurse

    Outline etiology and epidemiology of IBS-C and CIC in the U.S.
    Describe the FDA approved pharmacologic treatment options for IBS-C and CIC, beyond laxatives, to include novel targets, efficacy data, primary contraindications, and adverse effects.
    Identify strategies for pharmacists to assist in identifying inadequately treated patients and providing patient counseling regarding prescription treatment options that will facilitate communication with the physician.


    Pharmacist

    Outline etiology and epidemiology of IBS-C and CIC in the U.S.
    Describe the FDA approved pharmacologic treatment options for IBS-C and CIC, beyond laxatives, to include novel targets, efficacy data, primary contraindications, and adverse effects.
    Identify strategies for pharmacists to assist in identifying inadequately treated patients and providing patient counseling regarding prescription treatment options that will facilitate communication with the physician.


    Pharmacy Technician

    Identify common causes of IBS-C and CIC in the U.S.
    Identify FDA approved pharmacologic treatment options for IBS-C and CIC
    Recognize effective patient communication skills with the physician.

  • Activity Type

    Knowledge

    Universal Activity Number

    Nurse 0798-0000-18-066-H01-P

    Pharmacist 0798-0000-18-066-H01-P

    Pharmacy Technician 0798-0000-18-066-H01-T

    ACPE PharmCon, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

    In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

  • Faculty

    Ashish Advani, PharmD
    Clinical Associate Professor, Mercer University, Founder, InPharmD




HARDWARE REQUIREMENTS
Standard Windows/Mac System
iPad or iPhone
Minimum screen resolution: 1024x768
Speakers or headphones
 


SOFTWARE REQUIREMENTS
Microsoft Edge
Internet Explorer 8.0 or higher
Google Chrome
Safari
Firefox 3.0.3 or higher


NETWORK REQUIREMENTS
Broadband Internet Connection:
T1, Hi-speed DSL or Cable
4G cellular connection
 
 

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

 

©2015 PharmCon, lnc. All Rights Reserved | Terms & Conditions | Privacy PolicyContinuing Education For Healthcare Professionals
Developed By: ITB, Inc.